Peppermint Raises $4.7M for Clinical Trial Finance

Clinical research treats scientific precision as nonnegotiable, then often asks the teams running trials to reconstruct their own revenue from contracts, visit records, invoices and payment files that do not agree. Peppermint has raised a $4.7M Seed round to bring that same standard of precision to the financial work behind the science.

Moxxie led the financing, with Homebrew, Better Tomorrow Ventures, Layout Ventures, Digital Health Venture Partners, Night Capital, Benjamin Mann and Evan Moore participating. Peppermint announced the round on October 8, 2026, and said the money will support product expansion and hiring as it moves beyond collections into budget negotiation, expense management and clinical-trial analytics.

The bet is that research capacity depends on more than recruiting patients and executing protocols. A site can complete the visit, enter the data and still wait months to collect what it earned, leaving staff to chase invoices instead of supporting studies.

What Peppermint Is Building

Peppermint is a financial-operations platform for clinical research sites and health systems. The software connects to the systems a research organization already uses, including clinical trial management and accounting platforms, then reads visit activity, trial agreements, invoice history and remittance data to determine what should be billed and what has been paid.

The platform combines AI with human billing specialists. It validates billable activity against the contract, prepares invoices continuously rather than waiting for a monthly cycle, matches incoming payments to the exact visits they cover and supports collections when balances remain open. The result is meant to be a live, auditable ledger of every visit, invoice and dollar owed.

That architecture matters because clinical-trial finance is an unusually hostile environment for loose automation. Each study has its own agreement, schedule of events, payment rules and exceptions. A system can accelerate billing only if it preserves the evidence behind each line item well enough for sites, sponsors and contract research organizations to trust the result.

From X1 to Clinical Research

Co-founders David Freeman, Peppermint's CEO, and Vijay “VJ” Thurimella, its CTO, met at X1 as the company's first business hire and first engineer. They worked on payments and reconciliation infrastructure for the consumer credit-card business that Robinhood acquired in 2023 and later used to launch Robinhood Gold Card.

The connection is less about importing consumer-finance polish into healthcare than applying reconciliation discipline where money and records routinely arrive out of sequence. In both settings, an operation has to determine what should have happened, compare that expectation with what actually moved and preserve an audit trail when the two differ.

Peppermint says its partners now collect revenue 3x faster, have reduced overdue invoices threefold and have reclaimed 20% of staff time previously spent on billing. It also reports that the number of studies under management tripled in three months. Those are company-reported results rather than independently audited performance, but they describe the operating problem investors are underwriting.

Why Research-Site Cash Flow Matters

Research sites sit between patients, sponsors, contract research organizations and health systems. They hire coordinators, schedule visits, maintain regulatory records and perform the protocol work, yet payment may depend on several organizations reconciling activity across disconnected systems.

The financial pressure is not a minor administrative inconvenience. The Society for Clinical Research Sites has documented thin operating cushions and overdue receivables across the site ecosystem. When earned revenue remains trapped in reconciliation, the site effectively supplies working capital to the rest of the trial while carrying payroll and study expenses itself.

Peppermint's official site says the average site network may have $240K in unbilled or under-collected revenue and wait 94 days from visit completion to sponsor payment. The company also estimates that one experienced clinical billing specialist can cost more than $120K and support only 8 to 10 active sites. Those figures are Peppermint's own market framing, but they explain why software that recovers revenue without adding another coordinator workflow can become infrastructure rather than an accounting add-on.

What the $4.7M Changes

Peppermint plans to move beyond invoice generation and collections into budget negotiation, expense management and analytics. If the company can connect those functions to the same underlying record, finance leaders could see the revenue, cost and margin of an individual study or an entire research portfolio without rebuilding the answer in spreadsheets.

That expansion also raises the standard Peppermint must meet. Budget assumptions, visit activity, invoices, payments and expenses all carry different sources of truth, and clinical organizations cannot trade auditability for speed. The company's opportunity is to make the financial record behave more like the scientific one: traceable, reviewable and precise enough that the people doing the work can act on it.

The Seed round gives Peppermint room to build that broader ledger while its customers are still teaching the product where clinical-trial finance breaks. The useful outcome will show up far from the billing desk, in research teams that can see what their studies earn, recover it sooner and keep more operating capacity focused on the trials themselves.